Non-antibiotic drugs may accelerate antimicrobial resistance

Non-Antibiotic Drivers of Resistance

Specifically, common over-the-counter painkillers such as ibuprofen (Advil) and acetaminophen (Tylenol) have been linked to the acceleration of antibiotic resistance. Researchers found that these drugs can fuel bacterial resistance independently and may also enhance the effects of other resistance-promoting agents.

Impact on the Microbiome

Beyond direct resistance, non-antibiotic drugs can influence the body's internal microbial environment. A study published in Nature shows that these medications can alter the microbiome, which in turn increases the risk of gut infections.

Similar to how antibiotics kill beneficial bacteria alongside pathogens, non-antibiotic drugs can disrupt the balance of the microbiome. This disruption creates an environment where resistant bacteria may more easily proliferate or cause infection.

Environmental Contamination

The contribution of non-antibiotic drugs to AMR extends beyond the human body and into the environment. When humans or animals consume medications, as much as 90% of the drug can pass through the body and enter natural waterways,.

Research indicates that "cocktails" of these commonly used pharmaceuticals in waterways may promote the development of antibiotic-resistant bacteria. The presence of these mixtures in the environment creates a selective pressure that can exacerbate the development of AMR in wild bacterial populations,.

Broader Chemical Influence

In addition to pharmaceuticals, everyday chemical agents have played a role in the resistance landscape. The increased use of disinfectants, hand sanitizers, and antimicrobial sprays—particularly during the COVID-19 pandemic—has contributed to the prevalence of antimicrobial resistance. These chemicals are now ubiquitous in homes, hospitals, and public spaces, further exposing bacteria to agents that can trigger resistance mechanisms.

Potential for Drug Repurposing

While some non-antibiotic drugs contribute to resistance, other agents developed for different conditions may offer new therapeutic paths. Some drugs originally intended to treat mood disorders, inflammation, hyperlipidaemia, and pain management exhibit intrinsic or synergistic antimicrobial properties. This has led to interest in drug repurposing as a strategy to combat AMR.

A recent narrative review summarized various therapeutic approaches under development to tackle the rising tide of drug resistance, utilizing a "One Health" approach that considers the interconnectedness of human, animal, and environmental health.